不同基因型HCV及HCV、HBV重叠感染者对α-干扰素联合利巴韦林及胸腺肽治疗反应的比较

Study on the response to combined α-IFN, ribavilin and thymosin α_1 for different types HCV infection and HCV-HBV coinfection

为探讨不同基因型HCV及HCV、HBV重叠感染者对α -干扰素联合利巴韦林及胸腺肽治疗的反应 ,对171例接受干扰素联合利巴韦林治疗的HCV感染及HCV、HBV重叠感染者进行基因型调查 ,并分析对Ⅱ /1b型HCV感染的疗效。结果发现 ,Ⅳ /2b型HCV感染对干扰素联合利巴韦林治疗的应答率最高 (5 7 78% ) ,Ⅱ /1b型应答率最低 (11 76 % )。联合胸腺肽治疗的Ⅱ /1b型患者应答率高于干扰素联合利巴韦林治疗组 (P <0 0 5 ) ;Ⅱ /1b型HCV无论单独感染还是与HBV重叠感染均表现出更低的应答率。干扰素、利巴韦林联合胸腺肽治疗有助于提高Ⅱ

To Study on the response to combined α-IFN, ribavilin and thymosin α 1 for different types HCV infection and HCV-HBV coinfection. Genotypes of HCV in 171 patients with HCV infection and HCV-HBV coinfection were investigated and the patients were treated with IFN+ribavilin, curative effect of IFN+ribavilin to different type HCV infection, HCV-HBV coinfection and the response of HCV-Ⅱ/1b to IFN+ribavilin+Thymosin αl theapy were analyzed. The response rates in the four types HCV infection were different, HCV-Ⅳ/2b was the highest (57.78%),HCV-Ⅱ/1b was the lowest(11.76%). The response rate in those patients with HCV-Ⅱ/1b infection who treated with Thymosin αl was 46.15%,higher than those without Thymosinαl group, P<0.05;and the complete response rate was 30.76%,showed significant difference compared with the latter. In patients with HCV-HBV coinfection, the response rate to IFN+ribavilin was 11.11%,HCV Ⅱ/1b displayed the lowest response than other types when it infection alone, and presented more lower response when coinfected with HBV. The response rate could be raised if Thymosinα 1 were added.